New line of attack against advanced prostate cancer in a study led by a Catalan scientist
The Catalan Media Corporation, La Razón and Aldia.cat have highlighted a study conducted by Xavier Salvatella, ICREA researcher at IRB Barcelona, and published in the journal Structure early in December. In this work, he proposes various ways to tackle prostate cancer and focuses on the androgen receptor protein, which tumour cells need to survive and proliferate.
Link to CCMA
Link to La Razón
Link to Aldia.cat
Related content
News
Published in the journal Nature Cancer, the study analyses how genetic alterations in tumour cells prevent the correct degradation of the proteins involved in tumour development and growth, thereby leading to abnormal cell behaviour.
A machine-learning model has allowed the scientists to obtain the most extensive annotation of the ubiquitin-mediated protein degradation system.
The analysis proposes a potential new clinical approach for cancer through the inhibition of oncoproteins with impaired degradation systems.
The newspaper La Tribuna de Albacete has interviewed IRB Barcelona researcher Erika López Arribillaga about a grant awarded to her on 24 September by the Spanish Association Against Cancer (AECC). López Arribillaga’s project aims to unravel the long-term effects of some chemotherapy treatments on colorectal cancer patients.
Link to La Tribuna de Albacete
The newspapers El Mundo, La Vanguardia and Diari Ara, the TV station TV3 and the radio stationsCatalunya Ràdio andRAC1, among other media, have echoed on a study by the Biomedical Genommics lab, headed by Núria López, published in Nature Genetics. The study has for the first time determined the genetic mutations caused by various therapies used to treat cancer.
